Results

Scientific results are shown on posters at congresses

Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.

In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.

Here, we will give a short insight into our published results: Original publications

Eingeschlossene Patienten: 23.407 (Stand 03. März 2025)
Amgevita® (Adalimumab)248
Benepali® (Etanercept)1262
Cimzia® (Certolizumab)1046
Enbrel® (Etanercept)2877
Erelzi® (Etanercept)591
Flixabi® (Infliximab)10
Hukyndra® (Adalimumab)14
Hulio® (Adalimumab)284
Humira® (Adalimumab)2911
Hyrimoz® (Adalimumab)261
Idacio® (Adalimumab)69
Imraldi® (Adalimumab)239
Inflectra™ (Infliximab)16
Jyseleca® (Filgotinib)168
Kevzara® (Sarilumab)229
Kineret® (Anakinra)89
MabThera® (Rituximab)1459
Nepexto® (Etanercept)97
Olumiant® (Baricitinib)553
Orencia® (Abatacept)996
Remicade® (Infliximab)762
Remsima® (Infliximab)27
Rinvoq® (Upadacitinib)326
Rixathon® (Rituximab)20
RoActemra® (Tocilizumab)1379
Ruxience® (Rituximab)1
Simponi® (Golimumab)477
Truxima® (Rituximab)4
Tyenne® (Tocilizumab)55
Xeljanz® (Tofacitinib)403
Yuflyma® (Adalimumab)55
Zessly® (Infliximab)2
Kontrollen6477